These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 11070990

  • 1. [Prostate-specific antigen].
    Eide IA, Angelsen A.
    Tidsskr Nor Laegeforen; 2000 Sep 10; 120(21):2528-31. PubMed ID: 11070990
    [Abstract] [Full Text] [Related]

  • 2. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF, Mensink HJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1733-8. PubMed ID: 10494319
    [Abstract] [Full Text] [Related]

  • 3. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan 21; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 4. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H, Egawa S.
    Gan To Kagaku Ryoho; 2003 Jan 21; 30(1):11-5. PubMed ID: 12557698
    [Abstract] [Full Text] [Related]

  • 5. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD, Rittenhouse HG.
    Rinsho Byori; 2004 Mar 21; 52(3):223-30. PubMed ID: 15137320
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S, Suyama K, Matsumoto K, Kuwao S, Baba S.
    J Urol; 2002 Jan 21; 167(1):97-102. PubMed ID: 11743284
    [Abstract] [Full Text] [Related]

  • 8. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N, Ohyama C, Habuchi T.
    Gan To Kagaku Ryoho; 2005 Feb 21; 32(2):275-80. PubMed ID: 15751649
    [Abstract] [Full Text] [Related]

  • 9. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug 21; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients.
    Passadakis P, Ersoy F, Tam P, Memmos D, Siamopoulos K, Ozener C, Akçiçek F, Camsari T, Ates K, Ataman R, Vlachojannis J, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylali I, Arinsoy T, Stathakis C, Yavuz M, Tsakiris D, Dimitriades A, Yilmaz ME, Gültekin M, Karayalçin B, Challa A, Polat N, Oreopoulos DG.
    Adv Perit Dial; 2004 Aug 21; 20():203-8. PubMed ID: 15384827
    [Abstract] [Full Text] [Related]

  • 11. [The clinical value of prostate-specific antigen velocity as a method for prostate cancer detection].
    Ito K, Kubota Y, Yamanaka H.
    Nihon Rinsho; 1998 Aug 21; 56(8):2021-5. PubMed ID: 9750500
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan 21; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 13. [Prostate cancer].
    Uchida K, Akaza H.
    Gan To Kagaku Ryoho; 2001 Oct 21; 28(10):1469-74. PubMed ID: 11681260
    [Abstract] [Full Text] [Related]

  • 14. [Molecular forms of prostate-specific antigen and their clinical significance].
    Hilz H.
    Urologe A; 1995 Jul 21; 34(4):275-82. PubMed ID: 7545841
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen: current status.
    Lukes M, Urban M, Záleský M, Zachoval R, Herácek J, Zdárský E.
    Folia Biol (Praha); 2001 Jul 21; 47(2):41-9. PubMed ID: 11321246
    [Abstract] [Full Text] [Related]

  • 16. Tumour serum markers: clinical and economical aspects.
    Kardamakis D.
    Anticancer Res; 1996 Jul 21; 16(4B):2285-8. PubMed ID: 8694557
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL, Marberger M, Roehrborn CG.
    J Urol; 2006 May 21; 175(5):1657-62. PubMed ID: 16600723
    [Abstract] [Full Text] [Related]

  • 20. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H.
    Scand J Urol Nephrol; 2005 May 21; 39(1):49-55. PubMed ID: 15764271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.